US Patent & Trademark Office allows AVEO Oncology patent

US Patent & Trademark Office allows AVEO Oncology patent


BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — AVEO Oncology AVEO, an oncology-focused commercial-stage biopharmaceutical company dedicated to providing medicines that help cancer patients live better lives, announced today that the United States Patent and Trademark Office (“USPTO”) filed US Patent Application No. 17 /720,619 entitled “Use of tivozanib to treat patients with refractory cancer” (the “Application”). AVEO expects to receive an approval notice for this application. This application may be issued as a patent in 2022 and will provide patent protection in the United States for the claimed methods of using FOTIVDA through 2039.

A Notice of Permission is issued after the USPTO has ruled that a patent may be granted from a patent application. The majority of patent applications that receive a notice of allowance are issued as US patents once the grant fee is paid. However, a notice of allowance is not a guarantee that a patent will be granted.

“We are pleased with the progress we have made with the United States Patent and Trademark Office and the continued recognition of FOTIVDA for the treatment of refractory advanced RCC in patients who have received at least two prior cancer therapies,” said Michael Bailey, President from AVEO and Managing Director. “Once granted, this patent is expected to present a potential barrier to generic entry. It is part of our broader life cycle management strategy and is designed to expand the commercial opportunities of FOTIVDA after a long development path and relatively short exclusivity period since FOTIVDA’s approval by the US Food and Drug Administration in March 2021.”

If granted, AVEO plans to patent this patent in United States Food and Drug Administration Orange Book: Approved Drugs with Therapeutic Equivalency Ratings in relation to FOTIVDA with an expiry date of November 5, 2039.

About FOTIVDA® (tivozanib)

FOTIVDA® (tivozanib) is an oral,…

Read full story here

More to explorer